Compare Organon & Co. Common Stock (OGN) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Consumer Staples Select Sector SPDR Fund — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Consumer Staples Select Sector SPDR Fund trades at $86.39 (market cap $14.15B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 3.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Consumer Staples Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Consumer Staples Select Sector SPDR Fund for 73 Days on average.
| OGN | XLP | |
|---|---|---|
Market Cap | $3.62B | $14.15B |
Volume | 2,892,999 | 10,004,762 |
Sector | Health | — |
52-Week High | $13.81 | $90.00 |
52-Week Low | $5.70 | $75.61 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XLP trades at $84.19, down 0.26% on the day, with a bullish technical outlook supported by moving averages and ADX signals. Analyst consensus is unanimously positive with 100% buy ratings. Recent news highlights its competitive expense ratio and defensive appeal amid market volatility, with strong performance relative to discretionary sectors in 2026.
The ETF's low costs and sector resilience underpin a favorable outlook, though overbought RSI levels and interest rate sensitivity pose near-term risks. Institutional favor and dividend stability offer long-term value, but macroeconomic pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
